November 2013 PBAC Meeting Outcomes - Review Drug and Form Drug use and type Purpose of Review PBAC Recommendation CINACALCET, 30 mg, 60 mg and 90 mg, tablet Senisipar® - Amgen - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-01-19 17:21:09 Clinical research Science Drugs Cinacalcet Secondary hyperparathyroidism Clinical trial Amgen Placebo Hyperparathyroidism Medicine Health Pharmacology		November 2013 PBAC Meeting Outcomes - Review Drug and Form Drug use and type Purpose of Review PBAC Recommendation CINACALCET, 30 mg, 60 mg and 90 mg, tablet Senisipar® Add to Reading List Source URL: www.pbs.gov.au Download Document from Source Website File Size: 36,00 KB Share Document on Facebook

	Amgen-Scholars-US Program-OCT2016 DocID: 1vl38 - View Document
	Amgen-Scholars-Program-Japan-Translated-OCT2016 DocID: 1v8Op - View Document
	Amgen-Scholars-Program-Japan-Translated-OCT2016 DocID: 1uS7i - View Document
	Student Guide Amgen Scholars Programme Ludwig-Maximilians University Munich Undergraduate Summer Research 2018 European LMU Amgen Scholars Programme DocID: 1uMs7 - View Document
	Amgen-Scholars-Japan-Program-A4-OCT2016 DocID: 1uKFN - View Document